Meningioma - Pipeline Review, H2 2016
"Meningioma
- Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Meningioma Pipeline Review, H2 2016, provides an
overview of the Meningioma (Oncology) pipeline landscape.
A
meningioma is a type of tumor that develops from the meninges, the
membrane that surrounds the brain and spinal cord. There are three
layers of meninges, called the dura mater, arachnoid and pia mater.
Most meningiomas (90%) are categorized as benign tumors, with the
remaining 10% being atypical or malignant. There is no obvious cause
of a meningioma.
However,
this type of brain tumor is about three times more common in women
than in men. A meningioma can cause symptoms by pressing on the brain
or spinal cord.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Meningioma Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Meningioma
(Oncology), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Meningioma (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Meningioma
(Oncology) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Meningioma
(Oncology) therapeutics and enlists all their major and minor
projects.
-
The pipeline guide evaluates Meningioma (Oncology) therapeutics based
on mechanism of action (MoA), drug target, route of administration
(RoA) and molecule type.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Meningioma (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Meningioma (Oncology) pipeline depth and focus of Indication
therapeutics.
Comments
Post a Comment